TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04717245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene Vaginal
Description: Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 LASER
Description: LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microablative Fractional radiofrequency
Description: Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third.
Study: NCT00232544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecommunications system
Description: The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TLC-Control
Description: A TLC system for providing general health education
Study: NCT00672191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: HIV-1 Immune Therapy
Study: NCT02372578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pregabalin placebo
Description: oral
Study: NCT02076607

Intervention type: PROCEDURE
Intervention: Arthrodesis
Description: Posterior approach to toracolumbar spine fusion.

Intervention type: DEVICE
Intervention: Brace
Description: Toracolumbar imobilization
Study: NCT01421017

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT00443417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency
Study: NCT02401685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Description: Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary treatment
Description: Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
Study: NCT04820244

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03041948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric nerve block
Description: See arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal-epidural nerve block
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description
Study: NCT01364584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection 2.5 mcg-10 mcg BID
Study: NCT01599975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting methylphenidate
Description: Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting methylphenidate
Description: 18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: 2 tablets of matched placebo daily by mouth
Study: NCT00793195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Description: Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
Study: NCT05161416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bubble Blowing
Description: Active Distraction Methods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoon Watching
Description: Passive Distraction Methods
Study: NCT04220216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H4H fitness program
Description: 4 weekly, 1 hour exercise sessions
Study: NCT01410890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
Study: NCT05001334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo care training
Description: During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
Study: NCT03573934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: GLP-2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2+GIP
Description: GLP-2+GIP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03932877

Intervention type: OTHER
Intervention: MMP-14 and s-ENG levels
Description: Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.

Intervention type: OTHER
Intervention: MMP-14 and s-ENG levels
Description: Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.

Intervention type: OTHER
Intervention: MMP-14 and s-ENG levels
Description: Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.

Intervention type: OTHER
Intervention: MMP-14 and s-ENG levels
Description: Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
Study: NCT02984488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visits
Description: Endodontic treatment is done and completed in a single visit using protaper next rotary system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two visits
Description: Endodontic treatment is done and completed in two visits using protaper next rotary system.
Study: NCT04053257

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs
Description: Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients.
Study: NCT03976258

Intervention type: DRUG
Intervention: buprenorphine/naloxone
Description: This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: buprenorphine/naloxone
Description: This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: Methadone
Description: This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: Methadone
Description: This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: Naltrexone Injection
Description: This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: Naltrexone Injection
Description: This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

Intervention type: DRUG
Intervention: Heroin
Description: This is an observational study. Participants using heroin will be enrolled into this group.
Study: NCT04493996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
Study: NCT04344223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Shoe
Description: Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Shoe
Description: Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
Study: NCT04257201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow Oyster -- 84 g
Description: Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow Oyster -- 168 g
Description: Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White button -- 84 g
Description: Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White button -- 168 g
Description: Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will consume the standardized test day salad only
Study: NCT02690181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
Study: NCT03729648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Arts Therapy
Description: The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
Study: NCT04058444

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
Study: NCT04026321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 125mL/day
Description: SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 250mL/day
Description: SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 500mL/day
Description: SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 625mL/day
Description: SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
Study: NCT02724358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: iodized oil (5ml) + Pirarubicin (20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rg3
Description: 20mg, BID, maintained though Month 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACE + Rg3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protective therapy
Description: standard liver protective therapy
Study: NCT04642716

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva collection of patients and salivary free amino acids analysis
Study: NCT03677765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra- vs Infraclavicular approach using ultrasonography
Description: In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
Study: NCT03737136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
Study: NCT03958383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2
Description: A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Palliative radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human programmed death receptor (PD-1) blocking antibody, given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
Study: NCT02519608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)